Technical Analysis for VAXX - Vaxxinity, Inc.

Grade Last Price % Change Price Change
F 0.00 0.00% 0.00
VAXX closed down 50.0 percent on Wednesday, October 16, 2024, on 29 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 6
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -50.00%
50 DMA Resistance Bearish -50.00%
Shooting Star Candlestick Bearish -50.00%
Wide Bands Range Expansion -50.00%
Oversold Stochastic Weakness -50.00%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 22 hours ago
Gap Up Closed 2 days ago
50 DMA Resistance 2 days ago
20 DMA Resistance 2 days ago
10 DMA Resistance 2 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vaxxinity, Inc. Description

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing UB-313 that targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events, as well as UB-612/UB-612A for Covid-19 prevention. The company has a collaboration with United Biomedical, Inc. for the development of UB-612 in Taiwan. Vaxxinity, Inc. was founded in 2014 and is based in Dallas, Texas.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Alzheimer's Disease Parkinson's Disease Neurological Disorders Dementia Amyloidosis Neurodegenerative Disorders Lewy Body Dementia Migraine Multiple System Atrophy Neuropathology Pcsk9

Is VAXX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.45
52 Week Low 0.0001
Average Volume 12,614
200-Day Moving Average 0.48
50-Day Moving Average 0.04
20-Day Moving Average 0.03
10-Day Moving Average 0.01
Average True Range 0.07
RSI (14) 45.05
ADX 18.45
+DI 5.85
-DI 8.30
Chandelier Exit (Long, 3 ATRs) -0.12
Chandelier Exit (Short, 3 ATRs) 0.22
Upper Bollinger Bands 0.08
Lower Bollinger Band -0.03
Percent B (%b) 0.29
BandWidth 446.40
MACD Line -0.01
MACD Signal Line -0.01
MACD Histogram -0.0015
Fundamentals Value
Market Cap 225.74 Thousand
Num Shares 113 Million
EPS -0.53
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 4604.90
Price-to-Book 3.74
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.09
Resistance 3 (R3) 0.10 0.08 0.07
Resistance 2 (R2) 0.08 0.06 0.07 0.07
Resistance 1 (R1) 0.04 0.04 0.03 0.03 0.06
Pivot Point 0.02 0.02 0.02 0.02 0.02
Support 1 (S1) -0.02 0.00 -0.03 -0.03 -0.06
Support 2 (S2) -0.04 -0.01 -0.04 -0.07
Support 3 (S3) -0.08 -0.04 -0.07
Support 4 (S4) -0.09